Zevra Therapeutics Announces Positive Phase 2 Trial Of KP1077 For Idiopathic Hypersomnia

(RTTNews) - Zevra Therapeutics, Inc. (ZVRA) Monday announced a positive outcome in its placebo-controlled, double-blind Phase 2 clinical trial of KP1077 or serdexmethylphenidate or SDX in patients with idiopathic hypersomnia.

The proof-of-concept study was designed to demonstrate safety and tolerability and was well tolerated at all dose levels evaluated in the trial. The company presented the data in a poster at SLEEP 2024 in Houston, TX.

Adrian Quartel, chief medical officer of Zevra said, "We believe that KP1077 has great potential to provide a differentiated treatment option for patients underserved by currently available therapies."

Idiopathic hypersomnia is a rare sleep disorder characterized by excessive daytime sleepiness.

ZVRA is currently at $4.83, up 3.98 percent from the previous close of $4.65 on a volume of 108,488.